President Trump has made much, in public, of his zeal for lowering the “out of control” drug prices in the U.S. market. Choosing former Eli Lilly top exec Alex Azar to replace the disgraced Tom Price as Secretary of Health and Human Services will all but guarantee that doesn’t happen.
The case hinged on a little-known aspect of the Affordable Care Act that would expedite the release of generic drugs, a provision contested by major pharmaceuticals firms.
The Supreme Court dealt a blow to big pharma on Monday, ruling that companies making generic “biosimilars” to brand-name drugs don’t have to wait an extra six months after gaining federal approval before selling their drugs. The ruling, written by Justice Clarence